In addition, Kitange et al. showed that CD74 knockdown with shRNA reduced activation of Akt and ERK1/2, decreased proliferation and increased the sensitivity of glioma cells to TMZ (101). This evidence concerns the gene MAPK3 and central nervous system cancer.